The American Journal of Medicine
Volume 123, Issue 7, Supplement , Pages S9-S15 , July 2010

One Size Does Not Fit All: The Role of Vasodilating β-Blockers in Controlling Hypertension as a Means of Reducing Cardiovascular and Stroke Risk

  • Jan N. Basile, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Jan N. Basile, MD, Seinsheimer Cardiovascular Health Program, College of Medicine, Medical University of South Carolina, 171 Ashley Avenue, Charleston, South Carolina 29425-0950

References 

  1. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  2. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003
  3. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906
  4. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of β-blockers and diuretics precludes their use as first-line therapy in hypertension. Circulation. 2008;117:2706–2715
  5. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice?. Lancet. 2004;364:1684–1689
  6. Sarafidis PA, Bakris GL. Metabolic effects of β-blockers: importance of dissociating newer from conventional agents. J Hypertens. 2007;25:249–252
  7. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9:269–277
  8. Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9:667–676
  9. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9:866–875
  10. Greathouse M. Nebivolol efficacy and safety in patients with stage I-II hypertension. Clin Cardiol. 2010;33:E20–E27
  11. Carr AA, Weiss RJ. Significant blood pressure-lowering responses in nebivolol-treated patients assessed using stringent, clinically relevant criteria. J Clin Hypertens (Greenwich). 2008;10(suppl A):A117–A118
  12. Papademetriou V. Long-term efficacy of the highly cardioselective vasodilating β1-blocker nebivolol in patients without an initial response. J Clin Hypertens (Greenwich). 2008;10(suppl A):A124–A125
  13. Gradman AH. Safety and tolerability of nebivolol: a pooled safety analysis comparing typical β-blocker–associated adverse events with those of placebo. J Clin Hypertens (Greenwich). 2008;10(suppl A):A120
  14. Sowers J, Whaley-Connell A. Long-term effects of the novel β-blocker, nebivolol, on blood glucose in hypertensive patients. South Med J. 2008;101:863
  15. Giles T. Glucose control in hypertensive patients treated with the vasodilating, selective β-blocker, nebivolol. South Med J. 2008;101:863
  16. Bakris GL, Fonseca V, Katholi RE, et al. GEMINI Investigators Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–2236
  17. Flather MD, Shibata MC, Coats AJS, et al. SENIORS Investigators Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225
  18. Packer M, Coats AJS, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658
  19. Rosamond W, Flegal K, Friday G, et al. American Heart Association Statistics Committee and Stroke Statistics Committee Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–e171
  20. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405–412
  21. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? (A systematic review). JAMA. 1998;279:1903–1907
  22. Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? (A meta-analysis). Lancet. 2005;366:1545–1553
  23. Williams B, Lacy PS, Thom SM, et al. CAFE Investigators, the Anglo-Scandinavian Cardiac Outcomes Trial Investigators, and the CAFE Steering Committee and Writing Committee Differential impact of blood pressure–lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213–1225
  24. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007;(1):CD002003
  25. Cutler JA, Davis BR. Thiazide-type diuretics and β-adrenergic blockers as first-line drug treatments for hypertension. Circulation. 2008;117:2691–2705
  26. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344–348
  27. Bristow MR, Nelson P, Minobe W, Johnson C. Characterization of β1-adrenergic receptor selectivity of nebivolol and various other β-blockers in human myocardium. Am J Hypertens. 2005;18(suppl 4s):51A–52A
  28. Brixius K, Bundkirchen A, Bölck B, Melhorn U, Schwinger RHG. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol. 2001;133:1330–1338
  29. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795–3801
  30. Ignarro LJ. Experimental activity of nitric oxide-dependent vasodilatory activity of nebivolol, a third generation β-blocker. Blood Press Suppl. 2004;1:3–17
  31. Taylor AA, Bakris GL. The role of vasodilating β-blockers in patients with hypertension and the cardiometabolic syndrome. Am J Med. 2010;123(suppl):S21–S26
  32. Giles TD. The role of vasodilating β-blockers in patients with complicated hypertension: focus on nebivolol. Am J Med. 2010;123(suppl):S16–S20
  33. Cushman WC, Ford CE, Cutler JA, et al. ALLHAT Collaborative Research Group Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393–404
  34. Neutel JM, Smith DH, Gradman AH. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension. J Hum Hypertens. 2010;24:64–73
  35. Lacourcière Y, Lefebvre J, Poirier L, Archambault F, Arnott W. A double-blind crossover comparison of nebivolol and lisinopril in the treatment of ambulatory hypertension. Am J Ther. 1994;1:74–80
  36. Lacourcière Y, Poirier L, Lefebvre J, Provencher P, Arnott W. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol. 1992;32:660–666
  37. Uhlir O, Fejfusa M, Havranek K, et al. Nebivolol vs metoprolol in the treatment of hypertension. Drug Invest. 1991;3(suppl 1):107–110
  38. Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol. 2007;34:327–331
  39. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24:591–596

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

 Dr. Basile is supported by the National Heart, Lung, and Blood Institute (NHLBI) through funding for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and the Systolic Blood Pressure Intervention Trial (SPRINT).

PII: S0002-9343(10)00339-6

doi: 10.1016/j.amjmed.2010.04.013

The American Journal of Medicine
Volume 123, Issue 7, Supplement , Pages S9-S15 , July 2010

Article Tools

* Image Usage & Resolution